Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ETCompany ParticipantsThomas Kudsk - IRJiwon Oh - MD, PhD, St.

(Reuters) -The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €100.00.

FRANKFURT (Reuters) - Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a ...

Analyst Graham Parry of Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report), retaining the price ...

Follow Business Standard for the complete news coverage and key information about the Sanofi Consumer Healthcare India Ltd.

With a new production line, Sanofi aims to keep it and partner AstraZeneca’s drug Beyfortus in fully supply this RSV season.

Sanofi Consumer Healthcare has been listed on the BSE and NSE after its demerger from Sanofi India. Approved by the National ...